Science and Enterprise

Tag: equity

  • U.S. Angel Investors Retreating from Start Up Deals

    While angel investors made more deals in the first half of 2010, compared to 2009, the total dollar volume invested dropped, as did the percentage of funding for seed and start up stage financing. Nonetheless, a majority of the deals involved science-related companies. These findings appear in a report published by the Center for Venture…

  • Venture Investing Down in Q3, Up for Year-to-Date

    In the third quarter of 2010, venture capital (VC) investors put $5.5 billion into 662 deals for U.S.-based companies, down 5 percent in dollars invested but a 2 percent increase in deals from the same period last year, according to Dow Jones VentureSource. Science-based companies were among those experiencing a downturn in VC investments. For…

  • Venture Funding Down for Science Startups in Q3 2010

    Venture capital (VC) funding in the U.S. for new companies overall, including science-based enterprises, dropped in the third quarter of 2010, according to a new MoneyTree Report from PricewaterhouseCoopers and the National Venture Capital Association based on data provided by Thomson Reuters. Overall, VC companies invested $4.8 billion in 780 deals in the third quarter…

  • GlaxoSmithKline to Back Biotech Company

    Global drug maker GlaxoSmithKline (GSK), headquartered in London, says it will take an 18 percent equity stake in Convergence Pharmaceuticals Ltd., a new biotech company developing analgesic compounds, often used in over-the-counter pain relievers. Convergence Pharmaceuticals was officially launched on 4 October. The company has raised $35.4 million in Series A (early-stage) financing from a…

  • VC Mergers/Acquisitions Rebound, IPOs Drop in Q3 2010

    The number and value of U.S. disclosed venture capital (VC) exit deals in the third quarter of 2010 showed a mixed pattern compared to the second quarter of 2010, with more mergers and acquisitions (M&As) of VC-backed properties, but somewhat fewer initial public offerings (IPOs) of company stock. Exit deals — either M&As or IPOs…

  • Intel Invests in Four U.S. Technology Companies

    Intel Capital, the investment arm of Intel Corporation in Santa Clara, California, today revealed four investments totaling more than $30 million to growing technology companies in the U.S. The four companies represent the clean technology, cloud computing, and semiconductor manufacturing sectors. – Adaptive Computing in Provo, Utah provides intelligent automation software for high- performance computing,…

  • Mass. Start-Up Funding Drops 57% in July

    Early-stage companies based in Massachusetts attracted investments worth some $131.4 million in July 2010, a drop of 57 percent compared to the $307 million raised in June. The number of equity deals also dropped, from 31 in June to 26 in July. The Web site Xconomy reported these findings today based on data from the…

  • Financing Deals: 22 July 2010

    AxioMed Spine Corporation, a spinal orthopedics company developing products to restore spinal function in patients with degenerative spine disease, announced today that it has raised $14.5 million in two tranches from both current and new investors, not identified by the company. The funding will provide AxioMed with the ability to complete a study in the…

  • Financing Deals: 14 July 2010

    Pacific Biosciences in Menlo Park, California, a developer of molecular biology technology, announced completion of a new round of financing worth $109 million. This round includes a previously announced $50 million investment by Gen-Probe Inc., a maker of molecular diagnostic products and services. Hugh Martin, Pacific Biosciences’s chairman and CEO says the funding will be…

  • Financing Deals: 12 July 2010

    Accuri Cytometers in Ann Arbor, Michigan completed a $6 million financing deal involving sale of preferred stock to a group of investors including Arboretum Ventures, Baird Venture Partners, Fidelity Biosciences, Flagship Ventures and the InvestMichigan! Program co-managed by Credit Suisse. The company plans to use the financing to expand its C6 brand cytometer into the…